Literature DB >> 2570959

Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus.

G P Davidson1, P B Whyte, E Daniels, K Franklin, H Nunan, P I McCloud, A G Moore, D J Moore.   

Abstract

The efficacy of a 10-day course of bovine colostrum with high antibody titre against the four known human rotavirus serotypes in protecting children against rotavirus infection was examined in patients admitted to hospital. Children aged 3 to 15 months were blocked in pairs according to ward accommodation (ie, isolation or open area). Each block contained 1 treated and 1 control child. The allocation to treatment or control (an artificial infant formula) was randomised. 9 of 65 control children but none of 55 treated children acquired rotavirus infection during the treatment period (p less than 0.001). The importance of protecting against rotavirus infection was highlighted by the fact that parents of symptomatic rotavirus-positive children sought medical attention seven times more often than did parents of symptomatic rotavirus-negative children (p less than 0.05).

Entities:  

Keywords:  Antibodies; Australia; Biology; Delivery Of Health Care; Developed Countries; Diarrhea--prevention and control; Diseases; Health; Health Services; Immunity; Immunization; Immunologic Factors; Oceania; Physiology; Primary Health Care; Research Methodology; Study Design; Vaccination

Mesh:

Substances:

Year:  1989        PMID: 2570959     DOI: 10.1016/s0140-6736(89)90771-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

3.  Pedimune in recurrent respiratory infection and diarrhoea--the Indian experience--the pride study.

Authors:  Kamlesh Patel; Rajiv Rana
Journal:  Indian J Pediatr       Date:  2006-07       Impact factor: 1.967

4.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

5.  Thermal unfolding curves of high concentration bovine IgG measured by FTIR spectroscopy.

Authors:  V Sathya Devi; Denis R Coleman; Jeremy Truntzer
Journal:  Protein J       Date:  2011-08       Impact factor: 2.371

Review 6.  Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Authors:  D Carlander; H Kollberg; P E Wejåker; A Larsson
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

7.  Rotavirus outbreak in central Australia.

Authors:  Ged Williams; Linda Zerna
Journal:  Aust Infect Control       Date:  2016-03-17

Review 8.  Health factors in colostrum.

Authors:  B R Thapa
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967

9.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

Authors:  C P Kelly; C Pothoulakis; F Vavva; I Castagliuolo; E F Bostwick; J C O'Keane; S Keates; J T LaMont
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 10.  Is There a Role for the Enteral Administration of Serum-Derived Immunoglobulins in Human Gastrointestinal Disease and Pediatric Critical Care Nutrition?

Authors:  Melissa Van Arsdall; Ikram Haque; Yuying Liu; J Marc Rhoads
Journal:  Adv Nutr       Date:  2016-05-16       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.